Form 4: Elanco Animal Health Director Lawrence Kurzius Increases Stake in Company

Director Lawrence Erik Kurzius reports purchasing 20,000 shares of Elanco Animal Health Inc. (ELAN) in two transactions on March 7th and March 11th, 2025.

Summary

• Lawrence Erik Kurzius, a director of Elanco Animal Health Inc., has reported changes in beneficial ownership of the company's stock.
• On March 7, 2025, Kurzius purchased 10,000 shares of common stock at a price of $10.9 per share.
• Following this transaction, Kurzius directly owned 101,459 shares.
• On March 11, 2025, Kurzius purchased another 10,000 shares of common stock at a price of $10.2 per share.
• Following the second transaction, Kurzius directly owned 111,459 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's stock purchase suggests confidence, but it's a relatively small transaction in the grand scheme of the company's market capitalization.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies like Elanco Animal Health. Monitoring such filings can provide insights into management's sentiment and confidence in the company.

Stakeholder Impact

• The increased stake of a director could positively influence shareholder confidence.

Key Dates